Literature DB >> 29312797

Loss of ACVRIB leads to increased squamous cell carcinoma aggressiveness through alterations in cell-cell and cell-matrix adhesion proteins.

Holli A Loomans1,2, Shanna A Arnold3,4, Kate Hebron1, Chase J Taylor3,4, Andries Zijlstra1,4, Claudia D Andl1,5.   

Abstract

Squamous cell carcinomas of the head and neck (HNSCC) and esophagus (ESCC) pose a global public health issue due to high mortality rates. Unfortunately, little progress has been made in improving patient outcomes. This is partially a result of a lack of understanding the mechanisms that drive SCC progression. Recently, Activin A signaling has been implicated in a number of cancers, yet the role of this pathway in SCC remains poorly understood. We have previously discovered that the Activin A ligand acts as a tumor suppressor when epithelial Activin receptor type IB (ACVRIB) is intact; however, this effect is lost upon ACVRIB downregulation. In the present study, we investigated the function of ACVRIB in the regulation of SCC. Using CRISPR/Cas9-mediated ACVRIB-knockout and knockdown using siRNA, we found an increased capacity to proliferate, migrate, and invade upon ACRIB loss, as ACVRIB-KO cells exhibited an altered cytoskeleton and aberrant expression of E-cadherin and integrins. Based on chemical inhibitor studies, our data suggests that these effects are mediated through ACVRIB-independent signaling via downstream activation of Smad1/5/8 and MEK/ERK. Overall, we present a novel mechanism of SCC progression upon ACVRIB loss by showing that Activin A can transduce a signal in the absence of ACVRIB.

Entities:  

Keywords:  Activin A; adhesion; cytoskeleton dynamics; squamous cell carcinoma; three-dimensional culture

Year:  2017        PMID: 29312797      PMCID: PMC5752684     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  50 in total

Review 1.  Divide or Conquer: Cell Cycle Regulation of Invasive Behavior.

Authors:  Abraham Q Kohrman; David Q Matus
Journal:  Trends Cell Biol       Date:  2016-09-12       Impact factor: 20.808

2.  Activin A immunoexpression as predictor of occult lymph node metastasis and overall survival in oral tongue squamous cell carcinoma.

Authors:  Natalie Kelner; Priscila Campioni Rodrigues; Andreia Bufalino; Felipe Paiva Fonseca; Alan Roger dos Santos-Silva; Marcia Cristina Costa Miguel; Clóvis Antonio Lopes Pinto; Adriana Franco Paes Leme; Edgard Graner; Tuula Salo; Luiz Paulo Kowalski; Ricardo D Coletta
Journal:  Head Neck       Date:  2014-04-03       Impact factor: 3.147

3.  Coordinated functions of E-cadherin and transforming growth factor beta receptor II in vitro and in vivo.

Authors:  Claudia D Andl; Brenton B Fargnoli; Takaomi Okawa; Mark Bowser; Munenori Takaoka; Hiroshi Nakagawa; Andres Klein-Szanto; Xianxin Hua; Meenhard Herlyn; Anil K Rustgi
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

4.  Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients.

Authors:  Lai-ping Zhong; Chen-ping Zhang; Jia-wei Zheng; Jiang Li; Wan-tao Chen; Zhi-yuan Zhang
Journal:  Arch Oral Biol       Date:  2007-07-05       Impact factor: 2.633

Review 5.  Activins in reproductive biology and beyond.

Authors:  R Wijayarathna; D M de Kretser
Journal:  Hum Reprod Update       Date:  2016-02-15       Impact factor: 15.610

6.  Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.

Authors:  J M Alexander; H A Bikkal; N T Zervas; E R Laws; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

7.  The ALK-2 and ALK-4 activin receptors transduce distinct mesoderm-inducing signals during early Xenopus development but do not co-operate to establish thresholds.

Authors:  N A Armes; J C Smith
Journal:  Development       Date:  1997-10       Impact factor: 6.868

8.  Identification of molecular signature of head and neck cancer stem-like cells.

Authors:  Shubham Shrivastava; Robert Steele; Melanie Sowadski; Susan E Crawford; Mark Varvares; Ratna B Ray
Journal:  Sci Rep       Date:  2015-01-15       Impact factor: 4.379

9.  Esophageal squamous cell carcinoma invasion is inhibited by Activin A in ACVRIB-positive cells.

Authors:  Holli A Loomans; Shanna A Arnold; Laura L Quast; Claudia D Andl
Journal:  BMC Cancer       Date:  2016-11-09       Impact factor: 4.430

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  1 in total

1.  Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma.

Authors:  Katarina Pinjusic; Olivier Andreas Dubey; Olga Egorova; Sina Nassiri; Etienne Meylan; Julien Faget; Daniel Beat Constam
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.